自噬是一种降解功能失调蛋白质和细胞器的分解代谢过程,与癌症细胞在治疗、代谢应激、缺氧、饥饿和生长因子缺乏下的生存密切相关,在癌症进展的背景下,值得注意的是自噬被认为是一把“双刃剑”。三阴性乳腺癌(TNBC)是人类乳腺癌的一种亚型,是预后最差的亚型之一,TNBC的主要治疗方案包括手术、放疗、化疗和全身治疗。尽管最近在化疗方面取得了进展,但仍有40%的TNBC患者发生了转移性复发和复发。因此,探究TNBC的分子特征对于确定可选择的靶点以开发新的有效的治疗方法是必要的。近年来,自噬在TNBC进展中的关键作用逐渐显现。本篇自噬将关注中点关注自噬对TNBC关键靶点的作用以及探讨将自噬作为新的治疗模式的治疗方法。
Autophagy is a catabolic process that degrades dysfunctional proteins and organelle, which is closely related to the survival of cancer cells under treatment, metabolic stress, hypoxia, starvation and growth factor deficiency. In the context of cancer progression, it is worth noting that autophagy is considered a “double-edged sword”. Triple negative breast cancer (TNBC) is a subtype of human breast cancer with one of the worst prognosis. The main treatment options for TNBC include sur-gery, radiotherapy, chemotherapy and systemic therapy. Despite recent advances in chemotherapy, 40% of TNBC patients develop metastatic relapses and relapses. Therefore, it is necessary to ex-plore the molecular characteristics of TNBC to identify alternative targets for the development of new and effective therapies. In recent years, autophagy has gradually emerged as a key role in the development of TNBC. In this paper, autophagy will focus on the midpoint, the role of autophagy on the key targets of TNBC, and explore the therapeutic method of using autophagy as a new therapeu-tic mode.
自噬,三阴性乳腺癌,靶向治疗,抗肿瘤,耐药性, Autophagy Triple Negative Breast Cancer Targeted Therapy Anti-Tumor Drug Resistance摘要
Autophagy is a catabolic process that degrades dysfunctional proteins and organelle, which is closely related to the survival of cancer cells under treatment, metabolic stress, hypoxia, starvation and growth factor deficiency. In the context of cancer progression, it is worth noting that autophagy is considered a “double-edged sword”. Triple negative breast cancer (TNBC) is a subtype of human breast cancer with one of the worst prognosis. The main treatment options for TNBC include surgery, radiotherapy, chemotherapy and systemic therapy. Despite recent advances in chemotherapy, 40% of TNBC patients develop metastatic relapses and relapses. Therefore, it is necessary to explore the molecular characteristics of TNBC to identify alternative targets for the development of new and effective therapies. In recent years, autophagy has gradually emerged as a key role in the development of TNBC. In this paper, autophagy will focus on the midpoint, the role of autophagy on the key targets of TNBC, and explore the therapeutic method of using autophagy as a new therapeutic mode.
Keywords:Autophagy, Triple Negative Breast Cancer, Targeted Therapy, Anti-Tumor, Drug Resistance
吕 敏,山长平. 靶向自噬在三阴性乳腺癌中的应用Application of Targeted Autophagy in Triple Negative Breast Cancer[J]. 临床医学进展, 2023, 13(01): 62-67. https://doi.org/10.12677/ACM.2023.131010
参考文献ReferencesMizushima, N., et al. (2008) Autophagy Fights Disease through Cellular Self-Digestion. Nature, 451, 1069-1075.
<br>https://doi.org/10.1038/nature06639Levine, B. and Kroemer, G. (2008) Autophagy in the Pathogenesis of Disease. Cell, 132, 27-42.
<br>https://doi.org/10.1016/j.cell.2007.12.018Janji, B., et al. (2016) The Multifaceted Role of Autophagy in Tu-mor Evasion from Immune Surveillance. Oncotarget, 7, 17591-17607. <br>https://doi.org/10.18632/oncotarget.7540Amaravadi, R., Kimmelman, A.C. and White, E. (2016) Recent In-sights into the Function of Autophagy in Cancer. Genes & Development, 30, 1913-1930. <br>https://doi.org/10.1101/gad.287524.116Wang, X., et al. (2021) Progress of Breast Cancer Basic Research in China. International Journal of Biological Sciences, 17, 2069-2079. <br>https://doi.org/10.7150/ijbs.60631Manjunath, M. and Choudhary, B. (2021) Triple-Negative Breast Cancer: A Run-Through of Features, Classification and Current Therapies. Oncology Letters, 22, 512. <br>https://doi.org/10.3892/ol.2021.12773Behrends, C., et al. (2010) Network Organization of the Human Au-tophagy System. Nature, 466, 68-76.
<br>https://doi.org/10.1038/nature09204Rabinowitz, J.D. and White, E. (2010) Autophagy and Metabolism. Sci-ence, 330, 1344-1348.
<br>https://doi.org/10.1126/science.1193497Bai, Y., et al. (2019) PDIA6 Modulates Apoptosis and Autophagy of Non-Small Cell Lung Cancer Cells via the MAP4K1/JNK Signaling Pathway. EbioMedicine, 42, 311-325. <br>https://doi.org/10.1016/j.ebiom.2019.03.045Martini-Stoica, H., et al. (2016) The Autophagy-Lysosomal Pathway in Neurodegeneration: A TFEB Perspective. Trends in Neurosciences, 39, 221-234. <br>https://doi.org/10.1016/j.tins.2016.02.002Matsuzawa-Ishimoto, Y., Hwang, S. and Cadwell, K. (2018) Au-tophagy and Inflammation. Annual Review of Immunology, 36, 73-101. <br>https://doi.org/10.1146/annurev-immunol-042617-053253Kaushik, S., et al. (2021) Autophagy and the Hall-marks of Aging. Ageing Research Reviews, 72, Article ID: 101468.
<br>https://doi.org/10.1016/j.arr.2021.101468Galluzzi, L., et al. (2017) Molecular Definitions of Autophagy and Related Processes. The EMBO Journal, 36, 1811- 1836. <br>https://doi.org/10.15252/embj.201796697Yorimitsu, T. and Klionsky, D.J. (2005) Autophagy: Molecular Machinery for Self-Eating. Cell Death & Differentiation, 12, 1542-1552. <br>https://doi.org/10.1038/sj.cdd.4401765Glick, D., Barth, S. and Macleod, K.F. (2010) Autophagy: Cellular and Molecular Mechanisms. The Journal of Pathology, 221, 3-12. <br>https://doi.org/10.1002/path.2697Saftig, P., Beertsen, W. and Eskelinen, E.L. (2008) LAMP-2: A Control Step for Phagosome and Autophagosome Maturation. Autophagy, 4, 510-512. <br>https://doi.org/10.4161/auto.5724Liang, X.H., et al. (1999) Induction of Autophagy and Inhibition of Tumor-igenesis by Beclin 1. Nature, 402, 672-676.
<br>https://doi.org/10.1038/45257Laddha, S.V., et al. (2014) Mutational Landscape of the Essential Autophagy Gene BECN1 in Human Cancers. Molecular Cancer Research, 12, 485-490. <br>https://doi.org/10.1158/1541-7786.MCR-13-0614Loibl, S., et al. (2021) Breast Cancer. The Lancet, 397, 1750-1769. <br>https://doi.org/10.1016/S0140-6736(20)32381-3Singh, D.D. and Yadav, D.K. (2021) TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy. Biomedi-cines, 9, Article No. 876. <br>https://doi.org/10.3390/biomedicines9080876So, J.Y., et al. (2022) Triple Negative Breast Cancer (TNBC): Non-Genetic Tumor Heterogeneity and Immune Microenvironment: Emerging Treatment Op-tions. Pharmacology & Therapeutics, 237, Article ID: 108253.
<br>https://doi.org/10.1016/j.pharmthera.2022.108253Overgaard, J., et al. (2000) TP53 Mutation Is an Independ-ent Prognostic Marker for Poor Outcome in Both Node- Negative and Node-Positive Breast Cancer. Acta Oncologica, 39, 327-333.
<br>https://doi.org/10.1080/028418600750013096Chang, S.J., et al. (2016) Decreased Expression of Autophagy Protein LC3 and Stemness (CD44+/CD24-/Low) Indicate Poor Prognosis in Triple-Negative Breast Cancer. Human Pa-thology, 48, 48-55.
<br>https://doi.org/10.1016/j.humpath.2015.09.034Zhao, H., et al. (2013) High Expression of LC3B Is Associat-ed with Progression and Poor Outcome in Triple-Negative Breast Cancer. Medical Oncologist, 30, 475. <br>https://doi.org/10.1007/s12032-013-0475-1Ünal, T.D., et al. (2021) Thymoquinone Inhibits Proliferation and Migration of MDA-MB-231 Triple Negative Breast Cancer Cells by Suppressing Autophagy, Beclin-1 and LC3. An-ti-Cancer Agents in Medicinal Chemistry, 21, 355-364.
<br>https://doi.org/10.2174/1871520620666200807221047Lu, H.Y., et al. (2019) Hydroxytyrosol and Oleuro-pein Inhibit Migration and Invasion of MDA-MB-231 Triple-Negative Breast Cancer Cell via Induction of Autophagy. Anti-Cancer Agents in Medicinal Chemistry, 19, 1983-1990.
<br>https://doi.org/10.2174/1871520619666190722101207Hamurcu, Z., et al. (2018) Targeting LC3 and Beclin-1 Autophagy Genes Suppresses Proliferation, Survival, Migration and Invasion by Inhibition of Cyclin-D1 and uPAR/Integrin β1/Src Signaling in Triple Negative Breast Cancer Cells. Journal of Cancer Research and Clinical On-cology, 144, 415-430. <br>https://doi.org/10.1007/s00432-017-2557-5Pasculli, B., Barbano, R. and Parrella, P. (2018) Epigenetics of Breast Cancer: Biology and Clinical Implication in the Era of Precision Medicine. Seminars in Cancer Biology, 51, 22-35. <br>https://doi.org/10.1016/j.semcancer.2018.01.007Jovanovic, J., et al. (2010) The Epigenetics of Breast Cancer. Molecular Oncology, 4, 242-254.
<br>https://doi.org/10.1016/j.molonc.2010.04.002Fang, F., et al. (2011) Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis. Science Translational Medicine, 3, 75ra25. <br>https://doi.org/10.1126/scitranslmed.3001875Wong, K.K. (2021) DNMT1: A Key Drug Target in Tri-ple-Negative Breast Cancer. Seminars in Cancer Biology, 72, 198-213. <br>https://doi.org/10.1016/j.semcancer.2020.05.010Hamurcu, Z., et al. (2019) FOXM1 Plays a Role in Autoph-agy by Transcriptionally Regulating Beclin-1 and LC3 Genes in Human Triple-Negative Breast Cancer Cells. Journal of Molecular Medicine (Berlin), 97, 491-508.
<br>https://doi.org/10.1007/s00109-019-01750-8Xia, M., et al. (2021) Noncoding RNAs in Triple Negative Breast Cancer: Mechanisms for Chemoresistance. Cancer Letters, 523, 100-110. <br>https://doi.org/10.1016/j.canlet.2021.09.038Li, P.P., et al. (2021) LncRNA OTUD6B-AS1 Promotes Paclitaxel Resistance in Triple Negative Breast Cancer by Regulation of miR-26a-5p/MTDH Pathway-Mediated Au-tophagy and Genomic Instability. Aging (Albany NY), 13, 24171-24191. <br>https://doi.org/10.18632/aging.203672Zheng, X., et al. (2020) The circRNA circSEPT9 Mediated by E2F1 and EIF4A3 Facilitates the Carcinogenesis and Development of Triple-Negative Breast Cancer. Molecular Cancer, 19, 73.
<br>https://doi.org/10.1186/s12943-020-01183-9Ferreira, P.M.P., et al. (2021) Chloroquine and Hydroxychloro-quine in Antitumor Therapies Based on Autophagy-Related Mechanisms. Pharmacological Research, 168, Article ID: 105582. <br>https://doi.org/10.1016/j.phrs.2021.105582Hu, J., et al. (2019) ROS-Mediated Activation and Mito-chondrial Translocation of CaMKII Contributes to Drp1-Depen- dent Mitochondrial Fission and Apoptosis in Tri-ple-Negative Breast Cancer Cells by Isorhamnetin and Chloroquine. Journal of Experimental & Clinical Cancer Re-search, 38, 225. <br>https://doi.org/10.1186/s13046-019-1201-4Fleisher, B., et al. (2019) Chloroquine Sensitizes MDA-MB-231 Cells to Osimertinib through Autophagy-Apoptosis Crosstalk Pathway. Breast Cancer (Dove Med Press), 11, 231-241. <br>https://doi.org/10.2147/BCTT.S211030Liu, Z., et al. (2017) Autophagy Inhibitor Facili-tates Gefitinib Sensitivity in Vitro and in Vivo by Activating Mitochondrial Apoptosis in Triple Negative Breast Cancer. PLOS ONE, 12, e0177694.
<br>https://doi.org/10.1371/journal.pone.0177694Ren, H., et al. (2020) Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 63, 14609-14625. <br>https://doi.org/10.1021/acs.jmedchem.0c00873Wang, H., et al. (2022) Nanoprodrug Ratiometrically Integrat-ing Autophagy Inhibitor and Genotoxic Agent for Treatment of Triple-Negative Breast Cancer. Biomaterials, 283, Article ID: 121458.
<br>https://doi.org/10.1016/j.biomaterials.2022.121458Wu, M., et al. (2022) OSW-1 Induces Apoptosis and Cy-to-Protective Autophagy, and Synergizes with Chemotherapy on Triple Negative Breast Cancer Metastasis. Cellular On-cology (Dordrecht), 45, 1255-1275.
<br>https://doi.org/10.21203/rs.3.rs-910496/v1Zhen, Y., et al. (2020) Flubendazole Elicits Anti-Cancer Effects via Targeting EVA1A-Modulated Autophagy and Apoptosis in Triple-Negative Breast Cancer. Theranostics, 10, 8080-8097. <br>https://doi.org/10.7150/thno.43473Li, Q.W., et al. (2021) SANT, a Novel Chinese Herbal Monomer Combi-nation, Decreasing Tumor Growth and Angiogenesis via Modulating Autophagy in Heparanase Overexpressed Tri-ple-Negative Breast Cancer. Journal of Ethnopharmacology, 266, Article ID: 113430. <br>https://doi.org/10.1016/j.jep.2020.113430